14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Atypical meningeal localization of classical hairy cell leukemia with an impressive response to rituximab and cladribine association. A case report and literature review

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Hairy cell leukemia (HCL) is a rare lymphoproliferative disorder classically presenting with cytopenia and recurrent infections but atypical manifestations such as bone lesions, skin lesions and effusion have been described.

          We report here an unusual meningeal localization in a 33 years old man who presented with headache, hand paresthesia and visual symptoms. Brain magnetic resonance imaging revealed an occipital meningeal lesion. Diagnostic explorations led to the diagnosis of classical HCL with meningeal localization. After treatment by cladribine and rituximab the patient rapidly improved and is still in complete remission 12 months after end of treatment.

          The literature review identified 9 other cases of HCL with central nervous system localization (CNS) presenting with brain parenchyma and/or meninges localization. Four out of 9 patients presented with hyperleukocytosis. Most patients experienced good responses with various treatments. Cladribine alone or with rituximab led to complete responses similar to our patient. In our patient, molecular biology revealed KLF2 mutations, which implication in the atypical localization could be suspected but would need dedicated studies.

          In conclusion, CNS localizations of HCL are rare but can be observed and treatment with cladribine alone or with rituximab appears as an effective strategy.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression.

          The transcription factor Krüppel-like factor 2 (KLF2) is critical for normal trafficking of T lymphocytes, but its role in B cells is unclear. We report that B cell-specific KLF2 deficiency leads to decreased expression of the trafficking molecules CD62L and β7-integrin, yet expression of sphingosine-1 phosphate receptor 1 (which is a critical target of KLF2 in T cells) was, unexpectedly, minimally altered. Unexpectedly, Klf2 deletion led to a drastic reduction in the B1 B-cell pool and a substantial increase in transitional and marginal zone B-cell numbers. In addition, we observed that KLF2-deficient B cells showed increased apoptosis and impaired proliferation after B-cell receptor cross-linking. Gene expression analysis indicated that KLF2-deficient follicular B cells display numerous characteristics shared by normal marginal zone B cells, including reduced expression of several signaling molecules that may contribute to defective activation of these cells. Hence, our data indicate that KLF2 plays a critical role in dictating normal subset differentiation and functional reactivity of mature B cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

            In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.

              A large, multicentre, retrospective survey of patients with hairy cell leukaemia (HCL) was conducted in France to determine the frequency of second malignancies and to analyse the long-term effects of the established purine nucleoside analogues (PNAs), cladribine and pentostatin. The survey retrospectively reviewed the medical history of patients and their immediate family, clinical and biological presentation at the time of HCL diagnosis, treatment choice, response to treatment, time to relapse and cause of death. Data were collected for 487 patients with HCL. Of the patients included in the survey, 18% (88/487) had a familial history of cancers, 8% (41/487) presented with malignancies before HCL diagnosis and 10% (48/487) developed second malignancies after HCL was diagnosed. An excess incidence of second malignancies was observed, with a standardized incidence ratio (SIR) of 1·86 (95% confidence interval (CI): 1·34-2·51), with no significant difference between PNAs. For second haematological malignancies alone, the SIR was markedly increased at 5·32 (95% CI: 2·90-8·92). This study highlights the high frequency of cancers in HCL patients and their family members. The frequency of second malignancies is notably increased, particularly for haematological malignancies. The respective role of pentostatin and cladribine in the development of second malignancies is debatable.
                Bookmark

                Author and article information

                Contributors
                fclaves@chu-grenoble.fr
                Journal
                EJHaem
                EJHaem
                10.1002/(ISSN)2688-6146
                JHA2
                EJHaem
                John Wiley and Sons Inc. (Hoboken )
                2688-6146
                09 January 2024
                February 2024
                : 5
                : 1 ( doiID: 10.1002/jha2.v5.1 )
                : 242-246
                Affiliations
                [ 1 ] Hematology Department University Hospital of Grenoble Alpes Grenoble France
                [ 2 ] Grenoble Alpes University Grenoble France
                [ 3 ] Genetic of Hematological Malignancies Department University Hospital of Grenoble Grenoble France
                [ 4 ] Institute for Advanced Biosciences Grenoble France
                [ 5 ] Pathology Department Cochin University Hospital Paris France
                [ 6 ] University Hospital Caen Caen France
                [ 7 ] INSERM U1245 Normandie University Caen France
                [ 8 ] Pathology Department University Hospital of Grenoble Alpes Grenoble France
                [ 9 ] Hematology Department University Hospital Caen Caen France
                Author notes
                [*] [* ] Correspondence

                Fabien Claves, Hematology Department, University Hospital of Grenoble Alpes, Grenoble, France.

                Email: fclaves@ 123456chu-grenoble.fr

                Author information
                https://orcid.org/0009-0002-6468-0001
                https://orcid.org/0000-0002-5967-8225
                https://orcid.org/0000-0001-6863-9992
                Article
                JHA2841
                10.1002/jha2.841
                10887254
                38406549
                51155d9c-5e60-4017-9290-18230219ba9a
                © 2024 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 07 December 2023
                : 01 October 2023
                : 18 December 2023
                Page count
                Figures: 1, Tables: 1, Pages: 5, Words: 2387
                Categories
                Case Report
                Case Reports
                Custom metadata
                2.0
                February 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.8 mode:remove_FC converted:23.02.2024

                atypical localization,central nervous system,cladribine and rituximab,hairy cell leukemia

                Comments

                Comment on this article